AL102-504
11 evidence topics · 1 source
Objective
Absorption, metabolism, excretion, and mass balance of carbon-14-labeled varegacestat
Location and study date
Registry status, dates, and site
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “AL102-504” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-02-25” |
| Primary completion (actual) | “2025-03-11” |
| Study completion (actual) | “2025-03-26” |
| Last update posted | “2025-09-26” |
| Site | “Frontage Laboratories, Inc.”; “Secaucus” |
Study design
Single-center, open-label, single-dose radiolabel study
Registry design fields
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
Eligibility criteria
Healthy men aged 18 to 55 years
Exclusion of recent radiation exposure
Treatment
Single dose of carbon-14-labeled varegacestat as two oral capsules after an overnight fast
Study outcomes
Rationale for using mass balance recovery as the primary endpoint
Secondary endpoints: total radioactivity, pharmacokinetics, metabolite profile, and safety
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (actual) | “6” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- AL102-504 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2025-03-11, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the routes of elimination and the metabolite profile of varegacestat are unknown from public sources.
- The study enrolled 6 healthy men aged 18 to 55 years and gave a single dose of approximately 100 µCi of [14C]varegacestat, so it provides no data in women, in patients with desmoid tumors, or at steady state.